NEPH · Nephros Inc

Shares issued to reporting person in lieu of cash fees for board service.

Shares issued to reporting person in lieu of cash fees for board service.

Options to purchase 30,631 shares vest on 11/1/2024 and options to purchase the remaining 91,893 shares vest quarterly in 12 equal amounts commencing on 2/1/2025.

Options to purchase 89,291 shares vest on 5/5/24 and options to purchase 267,874 shares vest quarterly in 12 equal amounts commencing on 8/5/24.

Shares issued to reporting person in lieu of cash fees for board service.

Options to purchase 1,000 shares vest on 3/16/2027 and options to purchase the remaining 3,000 shares vest quarterly in 12 equal amounts commencing on 6/16/2027.

This option vests as to 4,410 shares on each of 6/16/25 and 6/16/26 and 4,409 options vest on 6/16/27.

Options to purchase 13,589 shares vest on 3/27/2026 and options to purchase the remaining 40,770 shares vest quarterly in 12 equal amounts commencing on 6/27/2026.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.237 to $2.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.2138 to $2.2276, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.25, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the set range set forth in this footnote.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Options to purchase 2,601 shares vest on 5/14/25 and options to purchase the remaining 7,805 shares vest quarterly in 12 equal amounts commencing on 8/14/25.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents an in-kind distribution by Wexford Capital LP ("Wexford Capital") to Arthur Amron that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration, in connection with his separation from service as an employee of Wexford Capital.

Represents an in-kind distribution by Wexford Capital LP ("Wexford Capital") to Arthur Amron that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration, in connection with his separation from service as an employee of Wexford Capital.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.3899 to $2.4857, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

On December 13, 2023, the Company granted 9,291 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Amron in respect of his services as a member of the Board of Directors of the Company for 2023. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). At the request of Mr. Amron, the Restricted Stock was granted to Wexford Capital LP. The Restricted Stock vests 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

Options to purchase 30,631 shares vest on 11/1/24 and options to purchase the remaining 91,893 shares vest quarterly in 12 equal amounts commencing on 2/1/25.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.73, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the set range set forth in this footnote.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

On January 5, 2023, the Company granted 27,613 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Amron in respect of his services as a member of the Board of Directors of the Company for 2022. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). At the request of Mr. Amron, the Restricted Stock was granted to Wexford Capital LP. The Restricted Stock vests 6 months following the grant date.

On January 5, 2023, the Company granted an option to purchase 7,080 shares of common stock of the Company (the "Option") in respect of the service by Mr. Amron as a member of the Board of Directors of the Company for 2022. The Option was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). At the request of Mr. Amron, the Option was granted to Wexford Capital LP. The Option vests as to 2,360 shares on each of 1/5/2023, 1/5/2024 and 1/5/2025.